Literature DB >> 27705747

Vascular action of bisphosphonates: In vitro effect of alendronate on the regulation of cellular events involved in vessel pathogenesis.

Pablo H Cutini1, María B Rauschemberger2, Marisa J Sandoval3, Virginia L Massheimer4.   

Abstract

In this work we investigate whether, despite the procalcific action of alendronate on bone, the drug would be able to regulate in vitro the main cellular events that take part in atherosclerotic lesion generation. Using endothelial cell cultures we showed that Alendronate (1-50μM) acutely enhances nitric oxide production (10-30min). This stimulatory action of the bisphosphonate involves the participation of MAPK signaling transduction pathway. Under inflammatory stress, the drug reduces monocytes and platelets interactions with endothelial cells induced by lipopolysaccharide. Indeed the bisphophonate exhibits a significant inhibition of endothelial dependent platelet aggregation. The molecular mechanism of alendronate (ALN) on leukocyte adhesion depends on the regulation of the expression of cell adhesion related genes (VCAM-1; ICAM-1); meanwhile the antiplatelet activity is associated with the effect of the drug on nitric oxide production. On vascular smooth muscle cells, the drug exhibits ability to decrease osteogenic transdifferentiation and extracellular matrix mineralization. When vascular smooth muscle cells were cultured in osteogenic medium for 21days, they exhibited an upregulation of calcification markers (RUNX2 and TNAP), high alkaline phosphatase activity and a great amount of mineralization nodules. ALN treatment significantly down-regulates mRNA levels of osteoblasts markers; diminishes alkaline phosphatase activity and reduces the extracellular calcium deposition. The effect of ALN on vascular cells differs from its own bone action. On calvarial osteoblasts ALN induces cell proliferation, enhances alkaline phosphatase activity, and increases mineralization, but does not affect nitric oxide synthesis. Our results support the hypothesis that ALN is an active drug at vascular level that regulates key processes involved in vascular pathogenesis through a direct action on vessel cells.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alendronate; Endothelial monocyte adhesion; Nitric oxide; Osteogenic markers; Platelet adhesion and aggregation; Vascular calcification

Mesh:

Substances:

Year:  2016        PMID: 27705747     DOI: 10.1016/j.yjmcc.2016.08.017

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  3 in total

1.  The isoflavone genistein enhances osteoblastogenesis: signaling pathways involved.

Authors:  Sabrina B Cepeda; Marisa J Sandoval; María Carla Crescitelli; María Belén Rauschemberger; Virginia L Massheimer
Journal:  J Physiol Biochem       Date:  2020-01-02       Impact factor: 4.158

2.  Comparison of Vascular Morphometry in Jawbones and Long Bones: Micro-CT Study in a Rat Model Treated with Zoledronic Acid.

Authors:  Jing Yi Wang; Ru Qing Yu; Lei Huo; Nian Jing Rao; Weijia William Lu; Li Wu Zheng
Journal:  Biomed Res Int       Date:  2021-05-12       Impact factor: 3.411

Review 3.  Natural and non-natural antioxidative compounds: potential candidates for treatment of vascular calcification.

Authors:  Chia-Ter Chao; Hsiang-Yuan Yeh; You-Tien Tsai; Pei-Huan Chuang; Tzu-Hang Yuan; Jenq-Wen Huang; Huei-Wen Chen
Journal:  Cell Death Discov       Date:  2019-11-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.